Mentice Q4 2023: Ability is nothing without opportunity - Redeye

Redeye updates its estimates and valuation following Mentice’s Q4 2023 report. The quarter featured rather anaemic sales growth and profitability, though its order intake and M&A bode well for continued profitable growth. Mentice opportunistically acquired all substantial assets from competitor Biomodex, complementing its existing product offering. We judge the company’s long-term prospects remain essentially unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/980615/mentice-q4-2023-ability-is-nothing-without-opportunity?utm_source=finwire&utm_medium=RSS